Login to Your Account

Ares Invests $13.5M in Santhera, Obtains 10.6% Stake in Firm

By Cormac Sheridan

Wednesday, November 12, 2008
Ares Life Sciences, a reported €1 billion (US$1.27 billion) investment vehicle established earlier this year by the Bertarelli family, former majority owners of Serono SA, has acquired a 10.6 percent stake in specialty pharmaceuticals firm Santhera Pharmaceuticals AG in return for CHF15.9 million (US$13.5 million). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription